Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNEL 1.5/30 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of acne vulgaris (for women ≥15 years who have reached menarche and desire an oral contraceptive)
Prevention of pregnancy
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic: ethinyl estradiol primarily via CYP3A4; norethindrone via reduction, sulfate and glucuronide conjugation. First-pass metabolism extensive. Enterohepatic recirculation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
EE: ~97% bound to albumin; NET: ~61% bound to albumin, ~36% bound to SHBG.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
EE: ~6.5 L/kg; NET: ~4 L/kg. Reflects extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
EE: ~40-45% (oral); NET: ~64% (oral) due to first-pass metabolism.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute hepatic disease, hepatic adenomas, or history of cholestatic jaundice with prior oral contraceptive use. For Child-Pugh A (mild impairment), no adjustment; for Child-Pugh B or C (moderate to severe), contraindicated.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy not established in pediatric patients; use only after menarche and as per adult dosing if post-menarche.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. No dose adjustment necessary if used in women over 40 years who are premenopausal and not at increased risk of cardiovascular disease; however, consider lower dose formulations for women over 35 who smoke or have other risk factors.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially >35 years) and with smoking intensity. Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders (DVT, PE, stroke, MI), especially in smokers >35 years. Hepatic neoplasia, gallbladder disease, hypertension, carbohydrate and lipid effects. Use caution with prediabetes/diabetes, migraine, SLE, hereditary angioedema. Discontinue if jaundice, visual disturbances, or suspected pregnancy. Do not use before menarche.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history), cerebrovascular or coronary artery disease, known or suspected breast cancer or other estrogen-sensitive neoplasia, undiagnosed abnormal genital bleeding, pregnancy, known or suspected pregnancy, liver tumors (benign or malignant) or active liver disease, age >35 years and smoking, hypersensitivity to any component.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions require restriction. Grapefruit juice may slightly increase ethinyl estradiol levels, but not clinically significant. Avoid St. John's Wort as it may reduce contraceptive efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. Postmarketing studies have not identified an increased risk of major birth defects or miscarriages with combined hormonal contraceptives (CHCs) prior to pregnancy or inadvertently during early pregnancy. However, CHCs are contraindicated during pregnancy because they provide no benefit and may cause fetal harm. First trimester: No increased risk of congenital anomalies from inadvertent use. Second and third trimesters: Administration during pregnancy has been associated with an increased risk of adverse outcomes including hepatotoxicity (jaundice, cholestasis), estrogen-induced fetal masculinization of female genitalia, and potential long-term effects from androgen exposure. Use is contraindicated once pregnancy is confirmed.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk. Estrogen-containing CHCs may reduce milk production and composition, particularly in the early postpartum period. The milk-to-plasma (M/P) ratio is approximately 0.6 for norethindrone and 0.01 for ethinyl estradiol. Use is not recommended during breastfeeding; progestin-only contraceptives are preferred alternatives.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dosing adjustments apply as Junel 1.5/30 is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic metabolism, volume of distribution, renal clearance) would theoretically require dose adjustments, but the product is not indicated for use during pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Junel 1.5/30 is a monophasic oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for contraception. The pill-free interval during the placebo week may trigger withdrawal bleeding. Consistent timing is crucial; a delay of more than 3 hours in taking the active pill requires backup contraception for 7 days. Consider potential drug interactions with hepatic enzyme inducers (e.g., rifampin, carbamazepine) that may reduce efficacy. Monitor blood pressure and liver function periodically.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time, starting on the first day of your menstrual period.,If you miss a pill, follow the package insert instructions: if missed for less than 12 hours, take it immediately and continue; if missed for more than 12 hours, take the last missed pill and use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, especially in the first few months.,Smoking increases the risk of serious cardiovascular side effects, especially in women over 35 years old.,If you experience severe headache, chest pain, leg pain, or vision changes, seek medical attention immediately.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNEL 1.5/30 vs ALYACEN 7/7/7, answered by our medical review team.
JUNEL 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNEL 1.5/30 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNEL 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNEL 1.5/30 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNEL 1.5/30 is classified as Category C. FDA Pregnancy Category X. Postmarketing studies have not identified an increased risk of major birth defects or miscarriages with combined hormonal contraceptives (CHCs) prior to p. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.